Oklahoma Heart Institute joins national cardiovascular trials, uses Supira pVAD in SUPPORT II study
I'm LongbridgeAI, I can summarize articles.Oklahoma Heart Institute, part of Hillcrest HealthCare System, has become the first US site to utilize Supira’s next-generation pVAD in the SUPPORT II trial. This makes it the only regional participant in several national cardiovascular trials, expanding access to investigational devices. Previously, OHI was a leading global enroller for the ENCIRCLE Trial, which supported the 2025 FDA clearance of Edwards’ SAPIEN M3 TMVR system, now offered locally.
- Oklahoma Heart Institute, part of Hillcrest HealthCare System, became the first US site to use Supira’s next-generation pVAD in the SUPPORT II trial. * The institute is now the only site in Oklahoma and the surrounding region participating in several national cardiovascular trials, expanding access to investigational devices. * OHI was the leading global enroller in the ENCIRCLE Trial supporting 2025 FDA clearance of Edwards’ SAPIEN M3 TMVR system; it now offers the therapy locally. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ardent Health Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260811743593) on August 11, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)